Stock Traders Purchase High Volume of Larimar Therapeutics Call Options (NASDAQ:LRMR)

Larimar Therapeutics, Inc. (NASDAQ:LRMR) was the recipient of unusually large options trading activity on Wednesday. Stock investors acquired 3,744 call options on the stock. This is an increase of 456% compared to the average volume of 673 call options.

Institutional Investors Weigh In On Larimar Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. CWM LLC grew its position in Larimar Therapeutics by 10.3% during the third quarter. CWM LLC now owns 36,013 shares of the company’s stock worth $116,000 after buying an additional 3,361 shares in the last quarter. BNP Paribas Financial Markets lifted its position in shares of Larimar Therapeutics by 75.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 10,146 shares of the company’s stock valued at $33,000 after acquiring an additional 4,376 shares during the period. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Larimar Therapeutics by 33.9% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 18,248 shares of the company’s stock worth $59,000 after purchasing an additional 4,619 shares in the last quarter. Velan Capital Investment Management LP grew its holdings in shares of Larimar Therapeutics by 17.9% during the 2nd quarter. Velan Capital Investment Management LP now owns 33,000 shares of the company’s stock worth $95,000 after purchasing an additional 5,000 shares in the last quarter. Finally, American Century Companies Inc. increased its position in shares of Larimar Therapeutics by 7.8% in the second quarter. American Century Companies Inc. now owns 69,285 shares of the company’s stock worth $200,000 after purchasing an additional 5,001 shares during the period. 91.92% of the stock is currently owned by institutional investors and hedge funds.

Larimar Therapeutics News Summary

Here are the key news stories impacting Larimar Therapeutics this week:

• Positive Sentiment: Lifesci Capital upgraded LRMR to a “Strong-Buy” and published Q4 2025 and FY2025 EPS estimates (Q4: ($0.41); FY2025: ($1.70)), signaling analyst confidence in the company’s outlook and supporting demand for the shares. MarketBeat Lifesci Note
• Positive Sentiment: Citigroup raised its price target to $14 (buy), and Wedbush reaffirmed an outperform rating with an $11 target — both represent substantial upside vs. the current level and underpin bullish analyst sentiment. Benzinga
• Positive Sentiment: Unusually large call-option activity occurred (several thousand calls bought), suggesting short-term bullish positioning by traders and contributing to intraday spikes before the equity raise announcement. (No direct article link provided)
• Positive Sentiment: Coverage and commentary explaining the intraday rally were published (coverage noted a ~22% intraday rise before the selloff), which can attract momentum buyers and increased attention. AAII Article
• Neutral Sentiment: The company initially announced a proposed $75M underwritten offering (preliminary press release) — this first filing signaled capital raise intent before the deal was upsized. GlobeNewswire – Proposed Offering
• Negative Sentiment: Larimar priced an upsized underwritten public offering of 20,000,000 shares at $5.00 per share (gross proceeds ~$100M) and granted a 30-day option for an additional 3,000,000 shares — direct dilution and increased share supply are the main catalysts pressuring the stock. GlobeNewswire – Priced Offering

Analyst Upgrades and Downgrades

Several brokerages have recently commented on LRMR. Wedbush reissued an “outperform” rating and issued a $11.00 target price on shares of Larimar Therapeutics in a report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Larimar Therapeutics in a research report on Thursday, January 22nd. Leerink Partners upgraded Larimar Therapeutics to a “strong-buy” rating in a report on Monday, January 5th. Lifesci Capital upgraded Larimar Therapeutics to a “strong-buy” rating in a research note on Tuesday. Finally, Citigroup lifted their price target on Larimar Therapeutics from $12.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $16.14.

Larimar Therapeutics Price Performance

Shares of NASDAQ:LRMR opened at $5.52 on Friday. The stock has a market cap of $456.95 million, a price-to-earnings ratio of -2.86 and a beta of 1.00. The company has a 50 day moving average of $3.53 and a 200-day moving average of $3.79. Larimar Therapeutics has a one year low of $1.61 and a one year high of $6.42.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc is based in Bala Cynwyd, Pennsylvania.